Biotech

All Articles

Merck ceases stage 3 TIGIT trial in bronchi cancer for futility

.Merck &amp Co.'s TIGIT system has gone through another trouble. Months after shuttering a phase 3 m...

After a challenging year, Exscientia folds right into Recursion

.After a year determined by pipe hairstyles, the shift of its own CEO and discharges, Exscientia wil...

Cullinan, after $25M deal, restore bispecific to Harbour

.Cullinan Therapy was excited sufficient along with Harbour BioMed's bispecific immune system reacto...

A more detailed examine Intense Biotech's Intense 15

.Within this full week's episode of "The Best Line," we are actually diving right into Strong Biotec...

Lilly experiences period 2 breakdown of tau-targeting med

.The confetti is actually still soaring from Eli Lilly's event celebrating the approval of Alzheimer...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our summary of notable leadership hirings, firings and retir...

Lykos will definitely ask FDA to rethink its own choice following being rejected of MDMA treatment for trauma

.Observing an inadequate revealing for Lykos Rehabs' MDMA prospect for trauma at a latest FDA adviso...

AN 2 one-halfs headcount, ceases phase 3 test after data dissatisfy

.AN2 Rehabs is actually reviewing its own business in action to lackluster midphase data, vowing to ...

Merck pays out $700M for bispecific, snooping autoimmune position as well as opportunity to test Amgen in cancer cells

.Merck &amp Co. is actually paying for $700 million in advance to test Amgen in a blood stream cance...

Gilead pays out J&ampJ $320M to exit licensing package for seladelpar

.With Gilead Sciences almost an FDA choice for its own liver ailment medication seladelpar, the firm...